PureTech Health (LON:PRTC) Hits New 1-Year Low - Should You Sell?

PureTech Health plc (LON:PRTC - Get Free Report)'s share price reached a new 52-week low on Friday . The company traded as low as GBX 131.80 ($1.70) and last traded at GBX 136.20 ($1.75), with a volume of 5294853 shares trading hands. The stock had previously closed at GBX 134.80 ($1.74).

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group reissued a "buy" rating and set a GBX 455 ($5.86) price target on shares of PureTech Health in a research report on Monday, December 16th.

PureTech Health Stock Down 3.9 %

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The firm has a 50-day moving average of GBX 144.22 and a 200 day moving average of GBX 153.05. The stock has a market capitalization of £378.05 million, a price-to-earnings ratio of -5.16 and a beta of 1.02.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.